The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 13, 2018, and indicated that it does not currently plan to convene an advisory committee meeting to discuss the NDA.
Revefenacin (TD-4208) is a novel investigational once-daily nebulized LAMA under FDA review for the treatment of moderate to very severe COPD.
Theravance Biopharma and its affiliates have partnered with Mylan and its affiliates on the development and commercialization of nebulized revefenacin products for COPD and other respiratory diseases.
Theravance Biopharma's pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions, primarily in the acute care setting.
The company's research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and intestinal tract in order to maximize patient benefit and minimize risk.
Celltrion launches AVTOZMA IV in the United States following FDA approval
Novartis to launch US direct-to-patient platform for Cosentyx
Vascarta completes VAS-101 osteoarthritis clinical trial
Sen-Jam Pharmaceutical and KVK Tech complete final development deliverables for SJP-002C
OSE Immunotherapeutics forms strategic alliance with Inserm Transfert and Nantes University
ResVita Bio completes face-to-face Pre-IND meeting with FDA for RVB-003
N4 Pharma advances RNA delivery breakthrough with SRI collaboration
EMA recommends marketing approval of Alvotech's Gobivaz biosimilar to Simponi
Evommune reveals further positive data from Phase 2 EVO756 trial
J & D Pharmaceuticals receives Orphan Drug Designation for JD-004
Ascletis presents Phase III results of denifanstat (ASC40) for acne treatment at EADV Congress 2025
Sanofi reports positive phase 2a results for brivekimig in hidradenitis suppurativa
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation